{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T22:49:06Z","timestamp":1767998946723,"version":"3.49.0"},"reference-count":178,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.intimp.2024.113848","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:36:48Z","timestamp":1734395808000},"page":"113848","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A review of the immunomodulatory properties of mesenchymal stem cells and their derived extracellular vesicles in small-cell and non-small-cell lung cancer cells"],"prefix":"10.1016","volume":"146","author":[{"given":"Radhwan Abdul","family":"Kareem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayder Naji","family":"Sameer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Yaseen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zainab H.","family":"Athab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohaned","family":"Adil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanan Hassan","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2024.113848_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154991","article-title":"MALAT1: a key regulator in lung cancer pathogenesis and therapeutic targeting","volume":"253","author":"Bhat","year":"2024","journal-title":"Pathol.-Res. Pract."},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cllc.2023.10.007","article-title":"Lung cancer in women: the past, present, and future","volume":"25","author":"Florez","year":"2024","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.intimp.2024.113848_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.engappai.2023.106902","article-title":"Lung-EffNet: lung cancer classification using EfficientNet from CT-scan images","volume":"126","author":"Raza","year":"2023","journal-title":"Eng. Appl. Artif. Intel."},{"issue":"8","key":"10.1016\/j.intimp.2024.113848_b0020","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000032899","article-title":"Non-small cell lung cancer (NSCLC): a review of risk factors, diagnosis, and treatment","volume":"102","author":"Alduais","year":"2023","journal-title":"Medicine"},{"key":"10.1016\/j.intimp.2024.113848_b0025","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.lungcan.2022.11.014","article-title":"Challenges in the treatment of small cell lung cancer in the era of immunotherapy and molecular classification","volume":"175","author":"Caliman","year":"2023","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0030","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cllc.2022.08.006","article-title":"Pathological stage N1 limited-stage small-cell lung cancer patients can benefit from surgical resection","volume":"24","author":"Yu","year":"2023","journal-title":"Clin. Lung Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2024.113848_b0035","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202308977","article-title":"Nanomedicine combats drug resistance in lung cancer","volume":"36","author":"Zheng","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.intimp.2024.113848_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.155907","article-title":"Exploring the potential of cryptochlorogenic acid as a dietary adjuvant for multi-target combined lung cancer treatment","volume":"132","author":"Bai","year":"2024","journal-title":"Phytomedicine"},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0045","article-title":"Development of a prognostic model for NSCLC based on differential genes in tumour stem cells","volume":"14","author":"Ma","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2024.113848_b0050","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1144653","article-title":"Nanomedicine in lung cancer immunotherapy","volume":"11","author":"Doroudian","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"8005","key":"10.1016\/j.intimp.2024.113848_b0055","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41586-024-07177-7","article-title":"Evolutionary trajectories of small cell lung cancer under therapy","volume":"627","author":"George","year":"2024","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.intimp.2024.113848_b0060","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nrc.2017.87","article-title":"Small-cell lung cancer: what we know, what we need to know and the path forward","volume":"17","author":"Gazdar","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.intimp.2024.113848_b0065","first-page":"620","article-title":"Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions","volume":"73","author":"Megyesfalvi","year":"2023","journal-title":"CA: Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.intimp.2024.113848_b0070","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41571-022-00718-x","article-title":"At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC","volume":"20","author":"Otano","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2024.113848_b0075","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.trsl.2010.06.007","article-title":"Stem cells and cell therapy approaches in lung biology and diseases","volume":"156","author":"Sueblinvong","year":"2010","journal-title":"Transl. Res."},{"issue":"11","key":"10.1016\/j.intimp.2024.113848_b0080","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.3390\/ijms20112790","article-title":"Stem cell therapies in kidney diseases: progress and challenges","volume":"20","author":"Rota","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0085","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/stem.2450","article-title":"Concise review: Human embryonic stem cells\u2014what have we done? What are we doing? Where are we going?","volume":"35","author":"Ilic","year":"2017","journal-title":"Stem Cells"},{"issue":"3","key":"10.1016\/j.intimp.2024.113848_b0090","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.kint.2018.08.046","article-title":"Infusion of third-party mesenchymal stromal cells after kidney transplantation: a phase I-II, open-label, clinical study","volume":"95","author":"Erpicum","year":"2019","journal-title":"Kidney Int."},{"issue":"3","key":"10.1016\/j.intimp.2024.113848_b0095","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1007\/s12015-024-10687-6","article-title":"Mesenchymal stem cell-based scaffolds in regenerative medicine of dental diseases","volume":"20","author":"Kiarashi","year":"2024","journal-title":"Stem Cell Rev. Rep."},{"issue":"2","key":"10.1016\/j.intimp.2024.113848_b0100","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1089\/ten.tec.2022.0200","article-title":"Clinically relevant mesenchymal stem\/stromal cell sheet transplantation method for kidney disease","volume":"29","author":"Oka","year":"2023","journal-title":"Tissue Eng. Part C Methods"},{"key":"10.1016\/j.intimp.2024.113848_b0105","first-page":"1","article-title":"Electric field-directed migration of mesenchymal stem cells enhances their therapeutic potential on cisplatin-induced acute nephrotoxicity in rats","author":"Abdelrahman","year":"2023","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"issue":"5","key":"10.1016\/j.intimp.2024.113848_b0110","doi-asserted-by":"crossref","DOI":"10.3390\/biom14050538","article-title":"MSC-based cell therapy in neurological diseases: a concise review of the literature in pre-clinical and clinical research","volume":"14","author":"Zhang","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.intimp.2024.113848_b0115","doi-asserted-by":"crossref","first-page":"793","DOI":"10.18632\/oncotarget.28672","article-title":"Mesenchymal stem cells-the secret agents of cancer immunotherapy: promises, challenges, and surprising twists","volume":"15","author":"Minev","year":"2024","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2024.113848_b0120","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s13402-019-00459-7","article-title":"The therapeutic potential of mesenchymal stem cells in lung cancer: benefits, risks and challenges","volume":"42","author":"Cortes-Dericks","year":"2019","journal-title":"Cell. Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2024.113848_b0125","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.3390\/ijms19082188","article-title":"Mesenchymal stem cell expressing TRAIL as targeted therapy against sensitised tumour","volume":"19","author":"Shaik Fakiruddin","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.intimp.2024.113848_b0130","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.3390\/cancers16111967","article-title":"Extracellular vesicles in lung cancer: implementation in diagnosis and therapeutic perspectives","volume":"16","author":"Carreca","year":"2024","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.intimp.2024.113848_b0135","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41419-022-05034-x","article-title":"Mesenchymal stem cell-derived extracellular vesicles for immunomodulation and regeneration: a next generation therapeutic tool?","volume":"13","author":"Kou","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2024.113848_b0140","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02663","article-title":"Therapeutic application of mesenchymal stem cells derived extracellular vesicles for immunomodulation","volume":"10","author":"Gomzikova","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.113848_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-020-1580-7","article-title":"Exosomal microRNA-144 from bone marrow-derived mesenchymal stem cells inhibits the progression of non-small cell lung cancer by targeting CCNE1 and CCNE2","volume":"11","author":"Liang","year":"2020","journal-title":"Stem Cell Res. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0150","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","article-title":"Lung cancer immunotherapy: progress, pitfalls, and promises","volume":"22","author":"Lahiri","year":"2023","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0155","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.annonc.2021.09.011","article-title":"Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy\u2013results from the randomised phase II ETOP\/IFCT 4-12 STIMULI trial","volume":"33","author":"Peters","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2024.113848_b0160","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.823618","article-title":"Immunotherapy in lung cancer: current landscape and future directions","volume":"13","author":"Mamdani","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.113848_b0165","first-page":"1","article-title":"Small cell lung cancer stem cells display mesenchymal properties and exploit immune checkpoint pathways in activated cytotoxic T lymphocytes","author":"Kursunel","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"issue":"5","key":"10.1016\/j.intimp.2024.113848_b0170","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/s41571-019-0316-z","article-title":"Immunotherapeutic approaches for small-cell lung cancer","volume":"17","author":"Iams","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.intimp.2024.113848_b0175","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s002620000111","article-title":"Resistance of ex vivo expanded CD3+ CD56+ T cells to Fas-mediated apoptosis","volume":"49","author":"Verneris","year":"2000","journal-title":"Cancer Immunol. Immunother."},{"issue":"2","key":"10.1016\/j.intimp.2024.113848_b0180","first-page":"640","article-title":"Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging","volume":"101","author":"Edinger","year":"2003","journal-title":"Blood, J. Am. Soc. Hematol."},{"issue":"12","key":"10.1016\/j.intimp.2024.113848_b0185","first-page":"3301","article-title":"Dual-functional capability of CD3+ CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity","volume":"118","author":"Pievani","year":"2011","journal-title":"Blood, J. Am. Soc. Hematol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0190","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12943-023-01926-4","article-title":"Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1\/PD-L1 blockade in the clinical spectrum of lung cancer","volume":"23","author":"Li","year":"2024","journal-title":"Mol. Cancer"},{"issue":"8","key":"10.1016\/j.intimp.2024.113848_b0195","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.cllc.2022.07.009","article-title":"A phase IB trial of autologous cytokine\u2010induced killer cells in combination with sintilimab, monoclonal antibody against programmed cell death\u20101, plus chemotherapy in patients with advanced non\u2010small\u2010cell lung cancer","volume":"23","author":"Zhou","year":"2022","journal-title":"Clin. Lung Cancer"},{"issue":"40","key":"10.1016\/j.intimp.2024.113848_b0200","doi-asserted-by":"crossref","first-page":"67129","DOI":"10.18632\/oncotarget.18004","article-title":"Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies","volume":"8","author":"He","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.intimp.2024.113848_b0205","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/cam4.371","article-title":"CTLA\u20104 blockade with ipilimumab: biology, safety, efficacy, and future considerations","volume":"4","author":"Camacho","year":"2015","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0210","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/14737140.2016.1123626","article-title":"Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer","volume":"16","author":"Dang","year":"2016","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"9","key":"10.1016\/j.intimp.2024.113848_b0215","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.3390\/cancers12092522","article-title":"Immunotherapy in small cell lung cancer","volume":"12","author":"Esposito","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2024.113848_b0220","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.635007","article-title":"Immunotherapy in treating EGFR-mutant lung cancer: current challenges and new strategies","volume":"11","author":"To","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2024.113848_b0225","series-title":"Seminars in Cancer Biology","article-title":"Small cell lung cancer: novel treatments beyond immunotherapy","author":"Meijer","year":"2022"},{"key":"10.1016\/j.intimp.2024.113848_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.116014","article-title":"The role of tumor-associated macrophages in lung cancer: from mechanism to small molecule therapy","volume":"170","author":"Zhou","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2024.113848_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104284","article-title":"Tumor-associated macrophages in non-small-cell lung cancer: from treatment resistance mechanisms to therapeutic targets","author":"Huang","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"7693","key":"10.1016\/j.intimp.2024.113848_b0240","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0245","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/cac2.12244","article-title":"Anti\u2010PD\u2010L1\/TGF\u2010\u03b2R fusion protein (SHR\u20101701) overcomes disrupted lymphocyte recovery\u2010induced resistance to PD\u20101\/PD\u2010L1 inhibitors in lung cancer","volume":"42","author":"Cheng","year":"2022","journal-title":"Cancer Commun."},{"issue":"7","key":"10.1016\/j.intimp.2024.113848_b0250","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jtho.2020.03.003","article-title":"Bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in second-line treatment of patients with NSCLC: results from an expansion cohort of a phase 1 trial","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.intimp.2024.113848_b0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2021.153723","article-title":"Cancer immunotherapy: challenges and limitations","volume":"229","author":"Taefehshokr","year":"2022","journal-title":"Pathol.-Res. Pract."},{"key":"10.1016\/j.intimp.2024.113848_b0260","article-title":"Gut microbial metabolites in lung cancer development and immunotherapy: novel insights into gut-lung axis","author":"Li","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2024.113848_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112053","article-title":"Anlotinib may enhance the efficacy of anti-PD1 therapy by inhibiting the AKT pathway and promoting the apoptosis of CAFs in lung adenocarcinoma","volume":"133","author":"Tang","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2024.113848_b0270","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s10147-016-0959-z","article-title":"PD-1\/PD-L1 blockade in cancer treatment: perspectives and issues","volume":"21","author":"Hamanishi","year":"2016","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2024.113848_b0275","article-title":"Cell adhesion molecules and immunotherapy in advanced non-small cell lung cancer: current process and potential application","volume":"13","author":"Yang","year":"2023","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2024.113848_b0280","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1159\/000351284","article-title":"Mesenchymal stem cells as vectors for lung cancer therapy","volume":"85","author":"Kolluri","year":"2013","journal-title":"Respiration"},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0285","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1186\/s13287-020-01855-9","article-title":"Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress","volume":"11","author":"Wu","year":"2020","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.intimp.2024.113848_b0290","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.624746","article-title":"The macrophage response is driven by mesenchymal stem cell-mediated metabolic reprogramming","volume":"12","author":"Luque-Campos","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.113848_b0295","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1007\/s00018-015-1995-y","article-title":"Macrophage polarization in pathology","volume":"72","author":"Sica","year":"2015","journal-title":"Cell. Mol. Life Sci."},{"issue":"5","key":"10.1016\/j.intimp.2024.113848_b0300","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.3390\/cells9051145","article-title":"Identifying the therapeutic significance of mesenchymal stem cells","volume":"9","author":"Mishra","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2024.113848_b0305","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1010399","article-title":"Recent advances to enhance the immunomodulatory potential of mesenchymal stem cells","volume":"13","author":"Sarsenova","year":"2022","journal-title":"Front. Immunol."},{"issue":"43","key":"10.1016\/j.intimp.2024.113848_b0310","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.18632\/oncotarget.27065","article-title":"CD90(low) MSCs modulate intratumoral immunity to confer antitumor activity in a mouse model of ovarian cancer","volume":"10","author":"Zeng","year":"2019","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.intimp.2024.113848_b0315","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1007\/s12015-023-10539-9","article-title":"Immunomodulatory mechanisms and therapeutic potential of mesenchymal stem cells","volume":"19","author":"Yang","year":"2023","journal-title":"Stem Cell Rev. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0320","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1634\/stemcells.2007-0554","article-title":"Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+ CD25highFOXP3+ regulatory T cells","volume":"26","author":"Selmani","year":"2008","journal-title":"Stem Cells"},{"issue":"8","key":"10.1016\/j.intimp.2024.113848_b0325","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1634\/stemcells.2006-0548","article-title":"Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism","volume":"25","author":"Djouad","year":"2007","journal-title":"Stem Cells"},{"issue":"6","key":"10.1016\/j.intimp.2024.113848_b0330","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.3892\/ijmm.2014.1705","article-title":"Differentiation of human amniotic fluid-derived mesenchymal stem cells into type II alveolar epithelial cells in vitro","volume":"33","author":"Li","year":"2014","journal-title":"Int. J. Mol. Med."},{"issue":"2","key":"10.1016\/j.intimp.2024.113848_b0335","doi-asserted-by":"crossref","first-page":"37","DOI":"10.62347\/JAWM2040","article-title":"Mesenchymal stromal cell-based therapy in lung diseases; from research to clinic","volume":"13","author":"Yuan","year":"2024","journal-title":"American Journal of Stem Cells"},{"issue":"3","key":"10.1016\/j.intimp.2024.113848_b0340","doi-asserted-by":"crossref","first-page":"220","DOI":"10.4161\/cam.20875","article-title":"Mesenchymal stem cells in tumor development: emerging roles and concepts","volume":"6","author":"Cuiffo","year":"2012","journal-title":"Cell Adh. Migr."},{"issue":"5","key":"10.1016\/j.intimp.2024.113848_b0345","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/path.5357","article-title":"Mesenchymal stromal cells in cancer: a review of their immunomodulatory functions and dual effects on tumor progression","volume":"250","author":"Galland","year":"2020","journal-title":"J. Pathol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0350","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/stem.1247","article-title":"Human bone marrow-derived mesenchymal stem cells suppress human glioma growth through inhibition of angiogenesis","volume":"31","author":"Ho","year":"2013","journal-title":"Stem Cells"},{"issue":"3","key":"10.1016\/j.intimp.2024.113848_b0355","first-page":"209","article-title":"Mesenchymal stem cells inhibit proliferation of lymphoid origin haematopoietic tumour cells by inducing cell cycle arrest","volume":"65","author":"Sarmadi","year":"2010","journal-title":"Med. J. Malaysia"},{"key":"10.1016\/j.intimp.2024.113848_b0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01208-w","article-title":"Mesenchymal stem\/stromal cells in cancer therapy","volume":"14","author":"Lan","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"17","key":"10.1016\/j.intimp.2024.113848_b0365","doi-asserted-by":"crossref","first-page":"13511","DOI":"10.3390\/ijms241713511","article-title":"The dual role of mesenchymal stem cells in cancer pathophysiology: pro-tumorigenic effects versus therapeutic potential","volume":"24","author":"Slama","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0370","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3892\/ijo.2015.3001","article-title":"Acquisition of new tumor cell properties by MSC-derived exosomes","volume":"47","author":"Yang","year":"2015","journal-title":"Int. J. Oncol."},{"issue":"9","key":"10.1016\/j.intimp.2024.113848_b0375","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/sj.leu.2402608","article-title":"Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins","volume":"16","author":"Konopleva","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.intimp.2024.113848_b0380","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10549-006-9449-8","article-title":"Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma","volume":"105","author":"Stoff-Khalili","year":"2007","journal-title":"Breast Cancer Res. Treat."},{"issue":"6","key":"10.1016\/j.intimp.2024.113848_b0385","doi-asserted-by":"crossref","first-page":"670","DOI":"10.4252\/wjsc.v16.i6.670","article-title":"Mesenchymal stem cells-extracellular vesicles alleviate pulmonary fibrosis by regulating immunomodulators","volume":"16","author":"Gao","year":"2024","journal-title":"World J. Stem Cells"},{"key":"10.1016\/j.intimp.2024.113848_b0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01141-y","article-title":"Therapeutic roles of mesenchymal stem cell-derived extracellular vesicles in cancer","volume":"14","author":"Weng","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2024.113848_b0395","article-title":"Role of exosomes for delivery of chemotherapeutic drugs","volume":"38","author":"Gebeyehu","year":"2021","journal-title":"Crit. Rev.\u2122 Ther. Drug Carr. Syst."},{"issue":"23","key":"10.1016\/j.intimp.2024.113848_b0400","doi-asserted-by":"crossref","first-page":"12259","DOI":"10.3390\/app122312259","article-title":"Origin and composition of exosomes as crucial factors in designing drug delivery systems","volume":"12","author":"Rech","year":"2022","journal-title":"Appl. Sci."},{"key":"10.1016\/j.intimp.2024.113848_b0405","doi-asserted-by":"crossref","first-page":"6917","DOI":"10.2147\/IJN.S264498","article-title":"Exosome: a review of its classification, isolation techniques, storage, diagnostic and targeted therapy applications","author":"Zhang","year":"2020","journal-title":"Int. J. Nanomed."},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0410","article-title":"Biological properties of extracellular vesicles and their physiological functions","volume":"4","author":"Y\u00e1\u00f1ez-M\u00f3","year":"2015","journal-title":"J. Extracell. Ves."},{"issue":"3","key":"10.1016\/j.intimp.2024.113848_b0415","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1039\/D2FO02013K","article-title":"Milk exosomes: an oral drug delivery system with great application potential","volume":"14","author":"Tian","year":"2023","journal-title":"Food Funct."},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12964-022-00959-4","article-title":"A review on exosomes application in clinical trials: perspective, questions, and challenges","volume":"20","author":"Rezaie","year":"2022","journal-title":"Cell Commun. Signal."},{"issue":"2","key":"10.1016\/j.intimp.2024.113848_b0425","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4236\/cm.2020.113007","article-title":"Exosomes in clinical trial and their production in compliance with good manufacturing practice","volume":"32","author":"Chen","year":"2020","journal-title":"Tzu-Chi Med. J."},{"key":"10.1016\/j.intimp.2024.113848_b0430","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.canlet.2021.11.015","article-title":"Mesenchymal stem cell-derived exosome: a tumor regulator and carrier for targeted tumor therapy","volume":"526","author":"Zhang","year":"2022","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0435","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12935-024-03379-1","article-title":"Increasing the sensitivity and accuracy of detecting exosomes as biomarkers for cancer monitoring using optical nanobiosensors","volume":"24","author":"Yasamineh","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.intimp.2024.113848_b0440","first-page":"1","article-title":"Mesenchymal stem cell (MSC)-derived exosomes as novel vehicles for delivery of miRNAs in cancer therapy","author":"Sohrabi","year":"2022","journal-title":"Cancer Gene Ther."},{"issue":"2","key":"10.1016\/j.intimp.2024.113848_b0445","doi-asserted-by":"crossref","DOI":"10.1002\/adbi.202101050","article-title":"Mesenchymal stem cell exosomes and cancer: controversies and prospects","volume":"6","author":"Yassine","year":"2022","journal-title":"Adv. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0450","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12964-022-01017-9","article-title":"The potential use of mesenchymal stem cells-derived exosomes as microRNAs delivery systems in different diseases","volume":"21","author":"Oveili","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.intimp.2024.113848_b0455","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.816656","article-title":"Mesenchymal stem cell-derived exosomes: toward cell-free therapeutic strategies in chronic kidney disease","volume":"9","author":"Cao","year":"2022","journal-title":"Front. Med."},{"issue":"7","key":"10.1016\/j.intimp.2024.113848_b0460","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.3390\/ijms23073829","article-title":"Mesenchymal stem cell-derived extracellular vesicles and their therapeutic use in central nervous system demyelinating disorders","volume":"23","author":"Allegretta","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-022-07569-7","article-title":"Human infrapatellar fat pad mesenchymal stem cells show immunomodulatory exosomal signatures","volume":"12","author":"Kouroupis","year":"2022","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.intimp.2024.113848_b0470","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14040733","article-title":"Mesenchymal stem cell-derived extracellular vesicles as non-coding RNA therapeutic vehicles in autoimmune diseases","volume":"14","author":"Martinez-Arroyo","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.intimp.2024.113848_b0475","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.2147\/IJN.S355366","article-title":"Targeted therapy for inflammatory diseases with mesenchymal stem cells and their derived exosomes: from basic to clinics","volume":"17","author":"Wang","year":"2022","journal-title":"Int. J. Nanomed."},{"issue":"3","key":"10.1016\/j.intimp.2024.113848_b0480","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14030618","article-title":"Recent advances in the application of mesenchymal stem cell-derived exosomes for cardiovascular and neurodegenerative disease therapies","volume":"14","author":"Yang","year":"2022","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.intimp.2024.113848_b0485","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1021\/acs.molpharmaceut.0c00976","article-title":"Treatment for hepatocellular carcinoma is enhanced when norcantharidin is encapsulated in exosomes derived from bone marrow mesenchymal stem cells","volume":"18","author":"Liang","year":"2021","journal-title":"Mol. Pharm."},{"issue":"11","key":"10.1016\/j.intimp.2024.113848_b0490","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1039\/D1NR08170E","article-title":"Engineered mesenchymal stem cell-derived exosomes with high CXCR4 levels for targeted siRNA gene therapy against cancer","volume":"14","author":"Xu","year":"2022","journal-title":"Nanoscale"},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0495","first-page":"1","article-title":"Engineering stem cells to produce exosomes with enhanced bone regeneration effects: an alternative strategy for gene therapy","volume":"20","author":"Li","year":"2022","journal-title":"J. Nanobiotechnol."},{"issue":"5","key":"10.1016\/j.intimp.2024.113848_b0500","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.biotechadv.2012.08.008","article-title":"Exosomes for drug delivery\u2014a novel application for the mesenchymal stem cell","volume":"31","author":"Lai","year":"2013","journal-title":"Biotechnol. Adv."},{"issue":"8","key":"10.1016\/j.intimp.2024.113848_b0505","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.biotechadv.2018.09.001","article-title":"Towards rationally designed biomanufacturing of therapeutic extracellular vesicles: impact of the bioproduction microenvironment","volume":"36","author":"Patel","year":"2018","journal-title":"Biotechnol. Adv."},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0510","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-021-02629-7","article-title":"Mesenchymal stem cells-derived exosomes for drug delivery","volume":"12","author":"Sun","year":"2021","journal-title":"Stem Cell Res. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0515","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-5876-9-47","article-title":"Enabling a robust scalable manufacturing process for therapeutic exosomes through oncogenic immortalization of human ESC-derived MSCs","volume":"9","author":"Chen","year":"2011","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.intimp.2024.113848_b0520","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3390\/cells9030660","article-title":"Boosting the biogenesis and secretion of mesenchymal stem cell-derived exosomes","volume":"9","author":"Wang","year":"2020","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.intimp.2024.113848_b0525","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1016\/j.ymthe.2018.09.015","article-title":"Exosomes produced from 3D cultures of MSCs by tangential flow filtration show higher yield and improved activity","volume":"26","author":"Haraszti","year":"2018","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2024.113848_b0530","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10565-019-09504-5","article-title":"Exosomes produced from 3D cultures of umbilical cord mesenchymal stem cells in a hollow-fiber bioreactor show improved osteochondral regeneration activity","volume":"36","author":"Yan","year":"2020","journal-title":"Cell Biol. Toxicol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0535","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-021-02190-3","article-title":"Hollow-fiber bioreactor production of extracellular vesicles from human bone marrow mesenchymal stromal cells yields nanovesicles that mirrors the immuno-modulatory antigenic signature of the producer cell","volume":"12","author":"Gobin","year":"2021","journal-title":"Stem Cell Res. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0540","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-020-01719-2","article-title":"Three-dimensional culture of MSCs produces exosomes with improved yield and enhanced therapeutic efficacy for cisplatin-induced acute kidney injury","volume":"11","author":"Cao","year":"2020","journal-title":"Stem Cell Res. Ther."},{"issue":"26","key":"10.1016\/j.intimp.2024.113848_b0545","doi-asserted-by":"crossref","first-page":"5158","DOI":"10.1038\/s41388-019-0782-x","article-title":"Hypoxia-induced tumor exosomes promote M2-like macrophage polarization of infiltrating myeloid cells and microRNA-mediated metabolic shift","volume":"38","author":"Park","year":"2019","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0550","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-40555-0","article-title":"Application of a flow-based hollow-Fiber co-culture system to study cellular influences under hyperglycemic conditions","volume":"9","author":"Ebrahim","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0555","doi-asserted-by":"crossref","DOI":"10.1080\/20013078.2018.1442088","article-title":"Scalable, cGMP-compatible purification of extracellular vesicles carrying bioactive human heterodimeric IL-15\/lactadherin complexes","volume":"7","author":"Watson","year":"2018","journal-title":"J. Extracell. Vesicles"},{"issue":"16","key":"10.1016\/j.intimp.2024.113848_b0560","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1089\/gen.35.16.15","article-title":"Continuous production of exosomes: utilizing the technical advantages of hollow-fiber bioreactor technology","volume":"35","author":"Whitford","year":"2015","journal-title":"Genet. Eng. Biotechnol. News"},{"issue":"3","key":"10.1016\/j.intimp.2024.113848_b0565","first-page":"823","article-title":"Bioglass enhances the production of exosomes and improves their capability of promoting vascularization","volume":"6","author":"Wu","year":"2021","journal-title":"Bioact. Mater."},{"issue":"4","key":"10.1016\/j.intimp.2024.113848_b0570","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3390\/jcm8040533","article-title":"Thrombin preconditioning of extracellular vesicles derived from mesenchymal stem cells accelerates cutaneous wound healing by boosting their biogenesis and enriching cargo content","volume":"8","author":"Sung","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.intimp.2024.113848_b0575","unstructured":"R.I.V. Docking, Rab GTPases, Directors of Vesicle Docking, 1998."},{"issue":"38","key":"10.1016\/j.intimp.2024.113848_b0580","doi-asserted-by":"crossref","first-page":"11247","DOI":"10.1021\/bi061307z","article-title":"The extended family of neutral sphingomyelinases","volume":"45","author":"Clarke","year":"2006","journal-title":"Biochemistry"},{"issue":"5867","key":"10.1016\/j.intimp.2024.113848_b0585","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1126\/science.1153124","article-title":"Ceramide triggers budding of exosome vesicles into multivesicular endosomes","volume":"319","author":"Trajkovic","year":"2008","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.intimp.2024.113848_b0590","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.3390\/cells10081959","article-title":"Mesenchymal stem cell-derived exosomes: applications in regenerative medicine","volume":"10","author":"Hade","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0595","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1089\/ten.teb.2014.0300","article-title":"Emerging roles for extracellular vesicles in tissue engineering and regenerative medicine","volume":"21","author":"Lamichhane","year":"2015","journal-title":"Tissue Eng. B Rev."},{"key":"10.1016\/j.intimp.2024.113848_b0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.116008","article-title":"Mesenchymal stem cell-derived exosomes as delivery vehicles for non-coding RNAs in lung diseases","volume":"170","author":"Feng","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2024.113848_b0605","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3389\/fcell.2020.00471","article-title":"Conditioned medium from azurin-expressing human mesenchymal stromal cells demonstrates antitumor activity against breast and lung cancer cell lines","volume":"8","author":"Silva","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113848_b0610","first-page":"134","article-title":"Effect of human Wharton's jelly mesenchymal stem cell secretome on proliferation, apoptosis and drug resistance of lung cancer cells","volume":"10","author":"Hendijani","year":"2015","journal-title":"Res. Pharm. Sci."},{"key":"10.1016\/j.intimp.2024.113848_b0615","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.omto.2020.09.005","article-title":"microRNA-130b-3p contained in MSC-derived EVs promotes lung cancer progression by regulating the FOXO3\/NFE2L2\/TXNRD1 axis","volume":"20","author":"Guo","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0620","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-020-01770-z","article-title":"Lung delivery of MSCs expressing anti-cancer protein TRAIL visualised with 89Zr-oxine PET-CT","volume":"11","author":"Patrick","year":"2020","journal-title":"Stem Cell Res. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0625","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41420-022-01283-z","article-title":"Mesenchymal stem cell-derived extracellular vesicles transfer miR-598 to inhibit the growth and metastasis of non-small-cell lung cancer by targeting THBS2","volume":"9","author":"Li","year":"2023","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.intimp.2024.113848_b0630","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2119\/molmed.2009.00059","article-title":"Intratracheal delivery of CX3CL1-expressing mesenchymal stem cells to multiple lung tumors","volume":"15","author":"Xin","year":"2009","journal-title":"Mol. Med."},{"issue":"9","key":"10.1016\/j.intimp.2024.113848_b0635","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/mt.2015.110","article-title":"Mesenchymal stromal cells for linked delivery of oncolytic and apoptotic adenoviruses to non-small-cell lung cancers","volume":"23","author":"Hoyos","year":"2015","journal-title":"Mol. Ther."},{"issue":"22","key":"10.1016\/j.intimp.2024.113848_b0640","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1111\/jcmm.17933","article-title":"Inhibitory role of bone marrow mesenchymal stem cells\u2010derived exosome in non\u2010small\u2010cell lung cancer: microRNA\u201030b\u20105p, EZH2 and PI3K\/AKT pathway","volume":"27","author":"Wu","year":"2023","journal-title":"J. Cell Mol. Med."},{"issue":"2","key":"10.1016\/j.intimp.2024.113848_b0645","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.lungcan.2011.07.001","article-title":"Mesenchymal stem cells enhance lung cancer initiation through activation of IL-6\/JAK2\/STAT3 pathway","volume":"75","author":"Hsu","year":"2012","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0650","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2174\/156800913804486665","article-title":"Experimental therapy for lung cancer: umbilical cord-derived mesenchymal stem cell-mediated interleukin-24 delivery","volume":"13","author":"Zhang","year":"2013","journal-title":"Curr. Cancer Drug Targets"},{"issue":"3","key":"10.1016\/j.intimp.2024.113848_b0655","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.prp.2019.01.013","article-title":"Effects of mesenchymal stem cells harboring the Interferon-\u03b2 gene on A549 lung cancer in nude mice","volume":"215","author":"Chen","year":"2019","journal-title":"Pathol.-Res. Pract."},{"key":"10.1016\/j.intimp.2024.113848_b0660","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.canlet.2018.04.026","article-title":"Knockdown of TGF-\u03b21 expression in human umbilical cord mesenchymal stem cells reverts their exosome-mediated EMT promoting effect on lung cancer cells","volume":"428","author":"Zhao","year":"2018","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0665","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/13102818.2020.1712257","article-title":"Human umbilical cord mesenchymal stem cells suppress lung cancer via TLR4\/NF-\u03baB signalling pathway","volume":"34","author":"Li","year":"2020","journal-title":"Biotechnol. Biotechnol. Equip."},{"issue":"4","key":"10.1016\/j.intimp.2024.113848_b0670","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1134\/S0022093023040105","article-title":"Mesenchymal stem cells carrying IFN-\u03b1 and IFN-\u03b2 overexpression genes inhibit non-small cell lung cancer via the JAK\/STAT pathway","volume":"59","author":"Chen","year":"2023","journal-title":"J. Evol. Biochem. Physiol."},{"issue":"6","key":"10.1016\/j.intimp.2024.113848_b0675","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1515\/oncologie-2023-0278","article-title":"MiR-100-5p transfected MSCs-derived exosomes can suppress NSCLC progression via PI3K-AKT-mTOR","volume":"25","author":"Wei","year":"2023","journal-title":"Oncologie"},{"key":"10.1016\/j.intimp.2024.113848_b0680","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1007\/s12094-018-1894-4","article-title":"Characterization of tumor-derived mesenchymal stem cells potentially differentiating into cancer-associated fibroblasts in lung cancer","volume":"20","author":"Arena","year":"2018","journal-title":"Clin. Transl. Oncol."},{"issue":"10","key":"10.1016\/j.intimp.2024.113848_b0685","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1158\/0008-5472.CAN-08-4698","article-title":"Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer","volume":"69","author":"Loebinger","year":"2009","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.intimp.2024.113848_b0690","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3390\/cancers11091261","article-title":"Targeting of CD133+ cancer stem cells by mesenchymal stem cell expressing TRAIL reveals a prospective role of apoptotic gene regulation in non-small cell lung cancer","volume":"11","author":"Shaik Fakiruddin","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2024.113848_b0695","doi-asserted-by":"crossref","first-page":"8425","DOI":"10.1007\/s13277-015-4746-7","article-title":"Human umbilical cord mesenchymal stem cells delivering sTRAIL home to lung cancer mediated by MCP-1\/CCR2 axis and exhibit antitumor effects","volume":"37","author":"Yan","year":"2016","journal-title":"Tumor Biol."},{"issue":"6b","key":"10.1016\/j.intimp.2024.113848_b0700","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1111\/j.1582-4934.2008.00317.x","article-title":"Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model","volume":"12","author":"Mohr","year":"2008","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.intimp.2024.113848_b0705","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1406268","article-title":"Non-small cell lung cancer cells and concomitant cancer therapy induce a resistance-promoting phenotype of tumor-associated mesenchymal stem cells","volume":"14","author":"Sentek","year":"2024","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113848_b0710","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.canlet.2014.07.047","article-title":"Mesenchymal stem cells in lung cancer tumor microenvironment: their biological properties, influence on tumor growth and therapeutic implications","volume":"353","author":"Liu","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2024.113848_b0715","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ebiom.2018.02.017","article-title":"Reciprocal modulation of mesenchymal stem cells and tumor cells promotes lung cancer metastasis","volume":"29","author":"Fregni","year":"2018","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.intimp.2024.113848_b0720","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1002\/jcp.27011","article-title":"Fusion with mesenchymal stem cells differentially affects tumorigenic and metastatic abilities of lung cancer cells","volume":"234","author":"Zhang","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"10","key":"10.1016\/j.intimp.2024.113848_b0725","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241423","article-title":"Mesenchymal stem cells promote metastasis through activation of an ABL-MMP9 signaling axis in lung cancer cells","volume":"15","author":"Gu","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0730","article-title":"Mesenchymal stem cells promote metastasis of lung cancer cells by downregulating systemic antitumor immune response","volume":"2017","author":"Gazdic","year":"2017","journal-title":"Stem Cells Int."},{"issue":"7","key":"10.1016\/j.intimp.2024.113848_b0735","doi-asserted-by":"crossref","first-page":"9780","DOI":"10.18632\/aging.202732","article-title":"Lung cancer-associated mesenchymal stem cells promote tumor metastasis and tumorigenesis by induction of epithelial\u2013mesenchymal transition and stem-like reprogram","volume":"13","author":"Yan","year":"2021","journal-title":"Aging (Albany NY)"},{"issue":"4","key":"10.1016\/j.intimp.2024.113848_b0740","doi-asserted-by":"crossref","DOI":"10.1016\/j.acthis.2023.152041","article-title":"Advantages of mesenchymal stem cell over the other stem cells","volume":"125","author":"Gopalarethinam","year":"2023","journal-title":"Acta Histochem."},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0745","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12717\/DR.2017.21.1.001","article-title":"Usage of human mesenchymal stem cells in cell-based therapy: advantages and disadvantages","volume":"21","author":"Kim","year":"2017","journal-title":"Dev. Reprod."},{"issue":"6","key":"10.1016\/j.intimp.2024.113848_b0750","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.stem.2012.08.013","article-title":"CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNF\u03b1","volume":"11","author":"Ren","year":"2012","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0755","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13062-024-00479-w","article-title":"Human lung cancer-derived mesenchymal stem cells promote tumor growth and immunosuppression","volume":"19","author":"Gao","year":"2024","journal-title":"Biol. Direct"},{"issue":"5","key":"10.1016\/j.intimp.2024.113848_b0760","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3892\/ol.2021.13046","article-title":"An overview of mesenchymal stem cells and their potential therapeutic benefits in cancer therapy","volume":"22","author":"Lim","year":"2021","journal-title":"Oncol. Lett."},{"issue":"8","key":"10.1016\/j.intimp.2024.113848_b0765","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1089\/wound.2022.0107","article-title":"Methods and limitations of augmenting mesenchymal stem cells for therapeutic applications","volume":"12","author":"Huerta","year":"2023","journal-title":"Adv. Wound Care"},{"issue":"7","key":"10.1016\/j.intimp.2024.113848_b0770","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1177\/0963689719837897","article-title":"The pros and cons of mesenchymal stem cell-based therapies","volume":"28","author":"Musia\u0142-Wysocka","year":"2019","journal-title":"Cell Transplant."},{"issue":"3","key":"10.1016\/j.intimp.2024.113848_b0775","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/bmt.2008.316","article-title":"Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium","volume":"43","author":"Von Bonin","year":"2009","journal-title":"Bone Marrow Transplant."},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0780","first-page":"430","article-title":"Immunogenicity of umbilical cord tissue\u2013derived cells","volume":"111","author":"Cho","year":"2008","journal-title":"Blood, J. Am. Soc. Hematol."},{"issue":"12","key":"10.1016\/j.intimp.2024.113848_b0785","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3390\/diagnostics10120999","article-title":"Clinical applications of mesenchymal stem\/stromal cell derived extracellular vesicles: therapeutic potential of an acellular product","volume":"10","author":"Massa","year":"2020","journal-title":"Diagnostics"},{"issue":"3","key":"10.1016\/j.intimp.2024.113848_b0790","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/med.22002","article-title":"Translating mesenchymal stem cell and their exosome research into GMP compliant advanced therapy products: promises, problems and prospects","volume":"44","author":"Ma","year":"2024","journal-title":"Med. Res. Rev."},{"issue":"4","key":"10.1016\/j.intimp.2024.113848_b0795","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/cncr.34576","article-title":"Baseline extracellular vesicle TGF\u2010\u03b2 is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancer","volume":"129","author":"de Miguel-Perez","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.intimp.2024.113848_b0800","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3389\/fcell.2020.00149","article-title":"Mesenchymal stem cell-derived extracellular vesicles: challenges in clinical applications","volume":"8","author":"Gowen","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"5","key":"10.1016\/j.intimp.2024.113848_b0805","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.4049\/jimmunol.176.5.2864","article-title":"The immunogenicity and immunomodulatory function of osteogenic cells differentiated from mesenchymal stem cells","volume":"176","author":"Liu","year":"2006","journal-title":"J. Immunol."},{"issue":"17","key":"10.1016\/j.intimp.2024.113848_b0810","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231710023","article-title":"Immunomodulatory mechanisms of mesenchymal stem cells and their potential clinical applications","volume":"23","author":"Huang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2024.113848_b0815","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10555-010-9222-7","article-title":"Bone marrow-derived mesenchymal stem cells and the tumor microenvironment","volume":"29","author":"Bergfeld","year":"2010","journal-title":"Cancer Metastasis Rev."},{"issue":"9","key":"10.1016\/j.intimp.2024.113848_b0820","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1002\/jcb.24166","article-title":"Functional heterogeneity of mesenchymal stem cells: implications for cell therapy","volume":"113","author":"Phinney","year":"2012","journal-title":"J. Cell. Biochem."},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0825","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12935-021-01836-9","article-title":"Mesenchymal stem cells and cancer therapy: insights into targeting the tumour vasculature","volume":"21","author":"Aravindhan","year":"2021","journal-title":"Cancer Cell Int."},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0830","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13045-021-01208-w","article-title":"Mesenchymal stem\/stromal cells in cancer therapy","volume":"14","author":"Lan","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"7659","key":"10.1016\/j.intimp.2024.113848_b0835","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/nature22341","article-title":"Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer","volume":"546","author":"Kamerkar","year":"2017","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.intimp.2024.113848_b0840","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3390\/jcm10040711","article-title":"Therapeutic features and updated clinical trials of mesenchymal stem cell (MSC)-derived exosomes","volume":"10","author":"Lee","year":"2021","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0845","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s13287-024-03868-0","article-title":"Safety and potential effects of intrathecal injection of allogeneic human umbilical cord mesenchymal stem cell-derived exosomes in complete subacute spinal cord injury: a first-in-human, single-arm, open-label, phase I clinical trial","volume":"15","author":"Akhlaghpasand","year":"2024","journal-title":"Stem Cell Res. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0850","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.apsb.2018.08.006","article-title":"Efficient lung cancer-targeted drug delivery via a nanoparticle\/MSC system","volume":"9","author":"Wang","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0855","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41392-021-00488-5","article-title":"Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial","volume":"6","author":"Shi","year":"2021","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"11","key":"10.1016\/j.intimp.2024.113848_b0860","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.jcyt.2016.09.003","article-title":"Genetically modified mesenchymal stromal cells in cancer therapy","volume":"18","author":"Sage","year":"2016","journal-title":"Cytotherapy"},{"issue":"4","key":"10.1016\/j.intimp.2024.113848_b0865","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10040804","article-title":"CAR-T cells\/-NK cells in cancer immunotherapy and the potential of MSC to enhance its efficacy: a review","volume":"10","author":"Chan","year":"2022","journal-title":"Biomedicines"},{"issue":"5","key":"10.1016\/j.intimp.2024.113848_b0870","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3727\/096368915X689622","article-title":"Clinical trials with mesenchymal stem cells: an update","volume":"25","author":"Squillaro","year":"2016","journal-title":"Cell Transplant."},{"key":"10.1016\/j.intimp.2024.113848_b0875","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-018-1078-8","article-title":"Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review","volume":"9","author":"Christodoulou","year":"2018","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.intimp.2024.113848_b0880","article-title":"Advances in mesenchymal stem cell-derived exosomes as drug delivery vehicles","volume":"9","author":"Rao","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113848_b0885","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41392-023-01382-y","article-title":"Engineered exosomes from different sources for cancer-targeted therapy","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"5","key":"10.1016\/j.intimp.2024.113848_b0890","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","article-title":"Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors","volume":"36","author":"Grosser","year":"2019","journal-title":"Cancer Cell"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924023701?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924023701?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T16:50:26Z","timestamp":1736614226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924023701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":178,"alternative-id":["S1567576924023701"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113848","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review of the immunomodulatory properties of mesenchymal stem cells and their derived extracellular vesicles in small-cell and non-small-cell lung cancer cells","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113848","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113848"}}